EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORMEWalter Stummer, Torsten Pietsch, Jörg‐Christian Tonn et al.|Neurosurgery|2008Cited by 1k
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trialUlrich Herrlinger, Martin Glas, Theophilos Tzaridis et al.|The Lancet|2019Cited by 581
Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection studyWalter Stummer, Uwe Pichlmeier, Jörg‐Christian Tonn et al.|Journal of neurosurgery|2010Cited by 300
5-Aminolevulinic Acid-derived Tumor FluorescenceWalter Stummer, Uwe Pichlmeier, Jörg‐Christian Tonn et al.|Neurosurgery|2013Cited by 274
Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls.Jörg‐Christian Tonn, Walter Stummer|PubMed|2008Cited by 161